VanEck Associates’s TG Therapeutics TGTX Stock Holding History

VanEck Associates’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$432K	Buy	+7,856	New	+$322K	﹤0.01%	1248
2025 Q4	–	Sell	-17,377	Closed	-$628K	–	1495
2025 Q3	$628K	Buy	17,377 +10,397	+149%	+$342K	﹤0.01%	1156
2025 Q2	$251K	Sell	6,980 -148,165	-96%	-$5.52M	﹤0.01%	1233
2025 Q1	$6.12M	Buy	155,145 +14,991	+11%	+$504K	0.01%	636
2024 Q4	$4.22M	Buy	+140,154	New	+$4.02M	0.01%	749
2021 Q2	–	Sell	-35,483	Closed	-$1.71M	–	1313
2021 Q1	$1.71M	Buy	+35,483	New	+$1.7M	﹤0.01%	642

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

VanEck Associates's TGTX Position: Q2 2026 in Review

VanEck Associates opened a new position in TG Therapeutics (TGTX) in Q2 2026: 7,856 shares worth $432K. The stake represents ﹤0.01% of the portfolio and ranks #1248 among its holdings. This is a return to the name: VanEck Associates previously reported a position in TGTX as recently as Q3 2025.

VanEck Associates first reported a position in TGTX in Q1 2021 and has held it in 6 quarters since. The position peaked at $6.12M in Q1 2025. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

VanEck Associates held 7,856 shares of TG Therapeutics worth $432K as of Q2 2026.
TG Therapeutics was a new VanEck Associates position in Q2 2026.
TG Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #1248 holding.
VanEck Associates first reported a position in TG Therapeutics in Q1 2021 and has held it in 6 quarters since.
VanEck Associates's TG Therapeutics position peaked at $6.12M in Q1 2025.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.